Efficacy Study of Rituximab After ASCT in High-Risk Diffuse Large B-Cell Lymphoma

Inclusion Criteria: * Patient with histologically proven CD20+ diffuse large B cell lymphoma (WHO Classification). * Aged from 18 to 59 years, eligible for transplant. * Patient not previously treated. * Age adjusted International Prognostic Index equal to 2 or 3. * Having previously signed a written informed consent. * Women of childbearing potential currently practicing an adequate method of contraception. Exclusion Criteria: * Any other histological type of lymphoma. * Any history of treated or non-treated indolent lymphoma. * Central nervous system or meningeal involvement by lymphoma. * Contra-indication to any drug contained in the chemotherapy regimens. * Poor renal function (creatinin level\>150mmol/l), poor hepatic function (total bilirubin level\>30mmol/l, transaminases\>2.5 maximum normal level) unless these abnormalities are related to the lymphoma. * Poor bone marrow reserve as defined by neutrophils \< 1.5 G/l or platelets \< 100 G/l, unless related to bone marrow infiltration. * Any history of cancer during the last 5 years, with the exception of non-melanoma skin tumors or stage 0 (in situ) cervical carcinoma. * Any serious active disease (according to the investigator's decision). * HIV, HTLV1 or HBV related disease. * Any organ transplantation before inclusion. * Pregnant women.